Results 171 to 180 of about 4,153 (212)
Some of the next articles are maybe not open access.
Finerenone — Halting Relative Hyperaldosteronism in Chronic Kidney Disease
New England Journal of Medicine, 2020Type 2 diabetes is the most common cause of chronic kidney disease (CKD) and end-stage renal disease.
Julie R, Ingelfinger, Clifford J, Rosen
openaire +2 more sources
In Brief: Finerenone (Kerendia) for Diabetic Kidney Disease
The Medical Letter on Drugs and Therapeutics, 2023Recently published guidelines from the American Diabetes Association (ADA) and the Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group recommend addition of the oral nonsteroidal mineralocorticoid receptor antagonist (MRA) finerenone (Kerendia) to standard treatment in patients with type 2 diabetes and chronic kidney disease (CKD).
openaire +2 more sources
Finerenone and diabetic renal disease: a narrative review
Journal of Prescribing PracticeOveractivation of mineralocorticoid receptors occurs in cardiorenal diseases. Many patients with type 2 diabetes often progress to chronic kidney disease (CKD) and require dialysis. Finerenone is the first oral non-steroidal mineralocorticoid receptor antagonist used in patients with diabetic kidney disease and heart failure. Finerenone (Kerendia®) is
Kirthika, Venkatesan +10 more
openaire +2 more sources
Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes
New England Journal of Medicine, 2021Bertram Pitt +2 more
exaly
Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes
Circulation, 2021Gerasimos Filippatos +2 more
exaly
Finerenone and Chronic Kidney Disease Outcomes in Type 2 Diabetes
New England Journal of Medicine, 2021Donald Baumstein
exaly